Yan Feng - Bristol-Myers Squibb | 人才画像

基本信息

浏览量：9

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 58 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Comprehensive Regulatory and Industry Review of Modeling and Simulation Practices in Oncology Clinical Drug Development

Ana Ruiz‐García,Paul Baverel,Dean Bottino,Michael Dolton,Feng Yan,Ignacio González‐García,Jaeyeon Kim,Seth Robey,Indrajeet Singh,David C. Turner, Shu-Pei Wu, Dong Yin,Di Zhou,Hao Zhu,Peter L. Bonate

Journal of pharmacokinetics and pharmacodynamics（2023）

引用2浏览0引用

Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Bruno Sangro,Thomas Yau,Anthony B. El-Khoueiry,Masatoshi Kudo,Yun Shen,Marina Tschaika,Amit Roy,Yan Feng,Ling Gao,Urvi Aras

Clinical and translational scienceno. 8 (2023): 1445-1457

引用0浏览0WOS引用

Clearance As an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology

Chengcong Chen,Xiaoqing Fan,Lin Zhang, Peng Xu,Huixi Zou,Xing Zhao,Manish Gupta,Yan Summer Feng,Xu Steven Xu,Xiaoyu Yan

Clinical Pharmacokineticsno. 5 (2023): 705-713

引用1浏览0WOS引用

Assessment of Hyperprogression Versus the Natural Course of Disease Development with Nivolumab with or Without Ipilimumab Versus Placebo in Phase III, Randomized, Controlled Trials

Yoon-Koo Kang,Martin Reck,Paul Nghiem,Yan Feng, Gregory Plautz,Hye Ryun Kim,Taofeek K. Owonikoko,Narikazu Boku,Li-Tzong Chen,Ming Lei,Han Chang,Wen Hong Lin,Amit Roy,Akintunde Bello,Jennifer Sheng

Journal for immunotherapy of cancer（2022）

引用6浏览0WOS引用

A HER2 Target Antibody Drug Conjugate Combined with Anti-Pd-(l)1 Treatment Eliminates Hher2+tumors in Hpd-1 Transgenic Mouse Model and Contributes Immune Memory Formation

Lei Huang,Ruiqin Wang,Kun Xie,Jingming Zhang,Fei Tao,Chenyu Pi,Yan Feng,Hua Gu,Jianmin Fang

BREAST CANCER RESEARCH AND TREATMENT（2022）

引用18浏览0引用

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

Chenyu Pi, Ping Jing,Bingyu Li,Yan Feng,Lijun Xu,Kun Xie,Tao Huang,Xiaoqing Xu,Hua Gu,Jianmin Fang

CANCERS（2022）

引用8浏览0WOS引用

Three Days of CIV Rh-Endostatin in Combination with PD-1 Antibody Plus Chemotherapy As First-Line Regimen for EGFR/ALK-negative, Advanced or Metastatic, Non-Squamous Non–small Cell Lung Cancer (NSCLC): A Open Label, Multicenter, Phase II and Cohort Study (ENPOWER)

Dong Wang,Yan Feng,Yuju Bai,Hu Ma, Li Huang, Tienian Zhu, Haihong Qian, Yanping Li,Xinjian Fang,Biyong Ren

Journal of Clinical Oncology（2022）

引用1浏览0引用

Targeting CD89 on Tumor-Associated Macrophages Overcomes Resistance to Immune Checkpoint Blockade

Lijun Xu,Bingyu Li,Chenyu Pi,Zhaohua Zhu,Fei Tao,Kun Xie,Yan Feng,Xiaoqing Xu,Yanxin Yin,Hua Gu,Jianmin Fang

Journal for immunotherapy of cancerno. 12 (2022): e005447-e005447

引用1浏览0引用

Efficacy and Safety of Toripalimab with Anlotinib and Chemotherapy As First-Line Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of an Open-Label, Single-Arm, Phase II Study

Hao Luo,Dan Jian,Yan Feng, Li Zhong,Qian Chen, Wei Guan,Shiheng Zhang,Jiamin Luo, Xueqing Yang,Kan Gong,Yanli Xiong,Mengxia Li,Mingfang Xu,Yu Pu,Liang Zhao,Chengyuan Qian,Nan Dai,Dong Wang

Journal of clinical oncology（2021）

引用4浏览0引用

Adaptive Resistance in Tumors to Anti-Pd-1 Therapy Through Re-Immunosuppression by Upregulation of GPNMB Expression

Xiaoqing Xu,Kun Xie,Bingyu Li,Lijun Xu, Lei Huang,Yan Feng,Chenyu Pi,Jingming Zhang,Tao Huang,Ming Jiang,Hua Gu,Jianmin Fang

International immunopharmacology (2021): 108199-108199

引用5浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn